statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 Shares

Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) CEO Douglas A. Treco sold 7,523 shares of the business's stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an...

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ( Company or Inozyme ), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ( the Company or Inozyme ), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

Inozyme Pharma (INZY, $7.3) RSI Indicator left the overbought zone on April 01, 2024

This is a signal that INZY's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Inozyme Pharma (INZY, $7.4) RSI Indicator left the overbought zone on March 27, 2024

Inozyme Pharma (INZY, $6.78) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 26, 2024

This is a Bullish indicator signaling INZY's price could rise from here. Traders may explore going long the stock or buying call options...

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq...

Equities Analysts Set Expectations for Inozyme Pharma, Inc.'s Q1 2024 Earnings (NASDAQ:INZY)

Inozyme Pharma, Inc. (NASDAQ:INZY  Free Report)  Investment analysts at HC Wainwright issued their Q1 2024 EPS estimates for Inozyme Pharma in a report issued on Wednesday, March 13th...

FY2024 EPS Estimates for Inozyme Pharma, Inc. Lowered by Analyst (NASDAQ:INZY)

Inozyme Pharma, Inc. (NASDAQ:INZY  Free Report)  Investment analysts at HC Wainwright cut their FY2024 EPS estimates for Inozyme Pharma in a report issued on Wednesday, March 13th...

Inozyme Pharma (NASDAQ:INZY) Rating Reiterated by Wedbush

Inozyme Pharma (NASDAQ:INZY  Get Free Report)s stock had its outperform rating reissued by research analysts at Wedbush in a research report issued on Tuesday, RTT News...

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Volume	189,757.00
52-Wk High	$7.80
52-Wk Low	$2.69

INZY Inozyme Pharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community